Search

Search bills, members, committees and pages...

H.R. 7291

U.S. HouseIn House Committee

Summary

H.R. 7291, the GRAS Oversight and Transparency Act, was introduced in the House on Jan 30, 2026 by Rep. Michael Lawler (R) with 1 co-sponsor. It was referred to Energy And Commerce, and last saw action on Jan 30, 2026: Referred to the House Committee on Energy and Commerce.


Record

Text

H.R. 7291 has 1 co-sponsor.

hb7291/introduced-in-house.txt
119 HR 7291 IH: GRAS Oversight and Transparency Act
U.S. House of Representatives
2026-01-30
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I 119th CONGRESS 2d Session H. R. 7291 IN THE HOUSE OF REPRESENTATIVES January 30, 2026 Mr. Lawler introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish a board to review certain designations that a substance used in food is generally recognized as safe, with respect to the intended use of such substance, and for other purposes.
1.
Short title
This Act may be cited as the GRAS Oversight and Transparency Act .
2.
GRAS review board; revocation of certain GRAS designations
(a)
Establishment
The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs (in this section referred to as the Secretary ), shall establish a board (in this section referred to as the Board ) to review the validity of covered GRAS designations.
(b)
Membership
(1)
In general
(A)
Voting members
The Board shall be composed of the following voting members:
(i)
The Secretary of Health and Human Services.
(ii)
The Secretary of Agriculture.
(iii)
Two representatives of the Human Foods Program of the Food and Drug Administration, to be appointed by the Secretary.
(iv)
One representative of each of the following organizations, to be appointed by the Secretary:
(I)
The Office of the Chief Counsel of the Food and Drug Administration.
(II)
The Office of the Chief Scientist of the Department of Agriculture.
(III)
The Office of the General Counsel of the Department of Agriculture.
(IV)
The Food Safety and Inspection Service of the Department of Agriculture.
(V)
The Center for Nutrition Policy and Promotion of the Department of Agriculture.
(VI)
The Agricultural Research Service of the Department of Agriculture.
(VII)
The Public Health and Integrated Toxicology Division of the Environmental Protection Agency.
(B)
Non-voting members
The Board shall be composed of the following non-voting members, to be appointed by the Secretary:
(i)
An academic expert in food toxicology.
(ii)
A representative from the food manufacturing industry.
(2)
Chairperson
The Secretary shall designate a chairperson of the Board from among the voting members described in paragraph (1).
(3)
Terms
Each voting and non-voting member of the Board appointed by the Secretary shall be appointed for a term of five years.
(4)
Compensation
Each member of the Board shall serve without compensation.
(c)
Duties
(1)
In general
The Board shall carry out a review of each covered GRAS designation in accordance with the requirements of this subsection.
(2)
Stages of review
In carrying out the review, the Board shall—
(A)
identify the scope of covered GRAS designations by soliciting the participation of food manufacturers under subsection (d);
(B)
categorize each covered GRAS designation so identified into a tier 1, tier 2, or tier 3 review category, with tier 1 indicating the highest priority for review;
(C)
carry out a review of the covered GRAS designations in each review category to determine the validity of each such designation; and
(D)
report the results of each such review in accordance with subsection (f).
(3)
Notification recommending revocation of GRAS designation
Not later than 90 days after the date on which the Board completes the review of a covered GRAS designation under paragraph (2)(C), the Board shall notify the Secretary and Congress of—
(A)
a determination that the substance that is the subject of such designation has not been shown to be safe; and
(B)
a recommendation that the Secretary revoke such designation under subsection (e).
(d)
Participation of food manufacturers
(1)
In general
The Secretary shall require a food manufacturer to provide to the Board, not later than 90 days after the date of enactment of this Act, a notice that—
(A)
identifies each covered GRAS designation attributable to such manufacturer; and
(B)
contains any other such information the Board determines to be appropriate.
(2)
Failure to comply
If a food manufacturer does not comply with paragraph (1), the Secretary may take actions to require such compliance, including—
(A)
imposing a civil penalty on such manufacturer in accordance with the amounts described in section 307(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 335b(a) ); or
(B)
with respect to a substance subject to a covered GRAS designation attributable to such manufacturer—
(i)
treating such substance as an unapproved food additive under section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ); and
(ii)
deeming such substance to be unsafe under such section as appropriate.
(e)
Revocation of certain GRAS designations
(1)
In general
Upon receiving a notification under subsection (c)(3), the Secretary may, using evidence before the Secretary, revoke a covered GRAS designation in accordance with the requirements under paragraph (2).
(2)
Requirements for revocation
If the Secretary decides to revoke a covered GRAS designation under paragraph (1), the Secretary shall—
(A)
notify the food manufacturer that provided a notice identifying such designation under subsection (d) of such decision, including a description of the evidence used in making such decision;
(B)
provide 180 days for such manufacturer to provide sufficient scientific evidence that the substance subject to such designation is shown to be safe;
(C)
review such decision using any such evidence; and
(D)
notify such manufacturer of the outcome of such review, including a description of how the Secretary carried out such review.
(3)
Compliance with revocation
The Secretary shall establish procedures to ensure a manufacturer complies with a revocation of a covered GRAS designation under this subsection, including an appropriate timeline for ceasing distribution of any substance subject to such designation and recalling such substance.
(f)
Reports
(1)
In general
The Board shall submit to the Secretary and Congress, and make publicly available on the website of the Food and Drug Administration, a report containing—
(A)
information related to the review carried out under subsection (c); and
(B)
any recommendation related to such review, including whether the Board made a notification under subsection (c)(3).
(2)
Timing of reports
A report shall be submitted under paragraph (1)—
(A)
with respect to a covered GRAS designation the Board categorizes into tier 1, not later than 2 years after the date of enactment of this Act;
(B)
with respect to a covered GRAS designation the Board categorizes into tier 2, not later than 4 years after the date of enactment of this Act; and
(C)
with respect to a covered GRAS designation the Board categorizes into tier 3, not later than 10 years after the date of enactment of this Act.
(g)
Definitions
In this section:
(1)
Covered GRAS designation
The term covered GRAS designation means a designation made by a manufacturer prior to 2000 that a substance used in food is generally recognized as safe, as described in section 201(s) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(s) ), including any such designation made in which such manufacturer has not filed a petition under section 409 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 348 ) or otherwise notified the Secretary of such designation.
(2)
Food
The term food has the meaning given such term in section 201(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(f) ).
(h)
Termination of Board
The Board shall terminate, and this Act shall cease to be effective, 10 years after the date of enactment of this Act.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2026-01-30
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish a board to review certain designations that a substance used in food is generally recognized as safe, with respect to the intended use of such substance, and for other purposes.

Sponsors

Rep. Michael Lawler (R) sponsors H.R. 7291, and 1 member has co-sponsored it.

Committees

H.R. 7291 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Jan 30, 2026 · 1,636 Bills

Actions

H.R. 7291 has taken 2 actions since Jan 30, 2026.

ChamberAction
Jan 30, 2026
House
Introduced in House
Jan 30, 2026
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 7291 has not gone to a roll call.

Titles

H.R. 7291 goes by 3 titles, 1 of them short titles.

  • GRAS Oversight and Transparency Act — Display Title
  • GRAS Oversight and Transparency Act — Short Title(s) as Introduced
  • To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to establish a board to review certain designations that a substance used in food is generally recognized as safe, with respect to the intended use of such substance, and for other purposes. — Official Title as Introduced

Lobbying

7 clients hired 7 firms and 110 registered lobbyists who named H.R. 7291 in 11 quarterly filings, 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Food Industry (safety, labeling, etc.), Environment/Superfund, Trade (domestic/foreign), Budget/Appropriations, Defense, Health Issues, Consumer Issues/Safety/Products, Immigration.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
CHAMBER OF COMMERCE OF THE U.S.A.District of Columbia13
FLEXIBLE PACKAGING ASSOCIATIONTrade association representing the flexible packaging industryMaryland12$60K
PHARMAVITE LLCCalifornia12
CONSUMER HEALTHCARE PRODUCTS ASSOCIATIONDistrict of Columbia11$199.8K
MONDELEZ INTERNATIONAL, INC.Snack companyDistrict of Columbia11$30K
INTERNATIONAL DAIRY FOODS ASSOCIATIONDistrict of Columbia11
UNILEVER UNITED STATES, INC.District of Columbia11

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 110.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
CHAMBER OF COMMERCE OF THE U.S.A.CHAMBER OF COMMERCE OF THE U.S.A.2026 first_quarter$19.8M1st Quarter - Amendme…
CHAMBER OF COMMERCE OF THE U.S.A.CHAMBER OF COMMERCE OF THE U.S.A.2026 first_quarter$19.8M1st Quarter - Report
CHAMBER OF COMMERCE OF THE U.S.A.CHAMBER OF COMMERCE OF THE U.S.A.2026 second_quarter$17M2nd Quarter - Report
INTERNATIONAL DAIRY FOODS ASSOCIATIONINTERNATIONAL DAIRY FOODS ASSOCIATION2026 second_quarter$270K2nd Quarter - Report
CONSUMER HEALTHCARE PRODUCTS ASSOCIATIONCONSUMER HEALTHCARE PRODUCTS ASSOCIATION2026 second_quarter$199.8K2nd Quarter - Report
UNILEVER UNITED STATES, INC.UNILEVER UNITED STATES, INC.2026 second_quarter$130K2nd Quarter - Report
PHARMAVITE LLCPHARMAVITE LLC2026 second_quarter$90K2nd Quarter - Report
PHARMAVITE LLCPHARMAVITE LLC2026 first_quarter$90K1st Quarter - Report
MONDELEZ INTERNATIONAL, INC.THE SMITH-FREE GROUP, LLC2026 second_quarter$30K2nd Quarter - Report
FLEXIBLE PACKAGING ASSOCIATIONCAPITOLINE CONSULTING, LLC2026 second_quarter$30K2nd Quarter - Report
FLEXIBLE PACKAGING ASSOCIATIONCAPITOLINE CONSULTING, LLC2026 first_quarter$30K1st Quarter - Report

Classification

The Congressional Research Service files H.R. 7291 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 7291’s is Health.

hr7291/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 7291, as entered in the Congressional Record.

[Congressional Record Volume 172, Number 22 (Friday, January 30, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LAWLER:H.R. 7291.Congress has the power to enact this legislation pursuantto the following:Article 1 Section 8 Clause 18 of the U.S. Constitution[Page H1922]

Source: congress.gov · legiscan.com